<DOC>
	<DOCNO>NCT00460447</DOCNO>
	<brief_summary>Study Design : prospective phase II trial 30 patient 1 site Treatment Scheme : Option 1 : Patient &lt; 60 year age relapse chemotherapy &gt; 12 month hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m² day –6 –3 TBI 2x2 Gy day –3 –2 ( total dose 8 Gy ) Tacrolimus ( level adapt ) day –3 Mycophenolat 2 x 1000 mg p.o . day 0 day 40 PBSC day 0 Option 2 : Patient &gt; 60 year age young patient &lt; 12 Months hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m² day –3 –1 TBI 1x2 Gy day 0 ( total dose 2 Gy ) Tacrolimus ( level adapt ) day –3 Mycophenolat 2 x 1000 mg p.o . day 0 40 PBSC day 0</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Scientific/Medical Rationale ( Objective ) : Primary : documentation extramedullary toxicity standard therapy Secondary : Induction persistent remission combination Mylotarg dose reduce conditioning follow allogenic hematopoetic stem cell transplantation patient relapse acute myelotic leukemia Study Design : prospective phase II trial 30 patient 1 site Treatment Scheme : Option 1 : Patient &lt; 60 year age relapse chemotherapy &gt; 12 month hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m² day –6 –3 TBI 2x2 Gy day –3 –2 ( total dose 8 Gy ) Tacrolimus ( level adapt ) day –3 Mycophenolat 2 x 1000 mg p.o . day 0 day 40 PBSC day 0 Option 2 : Patient &gt; 60 year age young patient &lt; 12 Months hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m² day –3 –1 TBI 1x2 Gy day 0 ( total dose 2 Gy ) Tacrolimus ( level adapt ) day –3 Mycophenolat 2 x 1000 mg p.o . day 0 40 PBSC day 0 Patient Population Included : 30 patient Primary Secondary Efficacy Endpoints : See point : Scientific/Medical Rationale Inclusion Criteria /Exclusion Criteria : - patient acute myelotic leukemia expression CD33 &gt; 5 % blast bone marrow - relapse chemotherapy - relapse autologous allogenic hematopoetic stem cell transplantation - pt .  2nd remission chemotherapy ineligible conventional allogeneic transplantation - age : 18-70 year - inform consent patient - ASAT/ ALAT &lt; 3fold upper standard - Bilirubin &lt; 2fold upper standard - ejection fraction &gt; 40 % echocardiography - potential donor accordance follow priority : - 1st HLA-identical relate donor ( HLA *A , *B , *C *DR ) - 2nd HLA-identical non-related donor maximum 1 allelmismatch ( DNA type A , B , C , DRB1 , DQB1 ) Study Procedures : See point . Study Design Safety Endpoints/ Statistical Considerations : Thirty patient treat , yield 95 % confidence interval non-relapse mortality precision +/- 14 % . Data evaluate group 10 20 patient . If result time suggest great 80 % confidence true rate day 100 non-relapse mortality exceed 20 % , trial stop . Operationally , occur 4 10 7 20 patient non-relapse death . Should requisite number death reach 10 20 patient benchmark , trial stop time . A dose reduction mylotarg 9 6 mg/m2 perform likelihood grade 4 liver-toxicity defined bilirubine , AST symptoms sinusoidal obstruction syndrome &gt; 20 % . This case 4 first ten patient experience grade 4 liver toxicity . The second dose mylotarg omit next ten patient . If rate liver-toxicity next 10 patient remain unchanged , study stop . The stopping rule discuss enforce protocol committee transmit local IRB asap . The following safety endpoint document : 1 . Incidence neurological toxicity 2 . Incidence liver toxicity 3 . Incidence acute gastrointestinal toxicity 4 . Incidence severity mucositis 5 . Incidence pulmonary toxicity 6 . Incidence systemic infection 7 . Duration neutropenia Severe adverse event ( SAE ) report principal investigator within 24 hour occurrence . It responsibility inform IRB sponsor trial , adequate . SAE compromise : death relapse leukemia , illness life-threatening character , severe illness require hospitalization , illness lead prolonged disability , second cancer develop treatment . SAE report special form contain CRF</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>patient acute myelotic leukemia expression CD33 &gt; 5 % blast bone marrow relapse chemotherapy relapse autologous allogenic hematopoetic stem cell transplantation pt . 2nd remission chemotherapy ineligible conventional allogeneic transplantation age : 1870 year informed consent patient ASAT/ ALAT &lt; 3fold upper standard Bilirubin &lt; 2fold upper standard ejection fraction &gt; 40 % echocardiography potential donor accordance follow priority : 1st HLAidentical relate donor ( HLA *A , *B , *C *DR ) 2nd HLAidentical nonrelated donor maximum 1 allelmismatch ( DNA type A , B , C , DRB1 , DQB1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>anti-CD33</keyword>
	<keyword>Immunotoxin</keyword>
	<keyword>Acute myeloid leukemia</keyword>
</DOC>